Intelligent Bio Solutions (INBS) Q4 2025 earnings summary

Executive summary

• Fiscal 2025 saw sequential and year-over-year revenue growth, driven by increased demand for drug testing cartridges and operational streamlining.

• The company advanced its U.S. FDA 510(k) clearance process, aiming to expand beyond Forensic Use Only settings.

• International commercial presence expanded to over 450 active accounts across 24 countries, supported by 18 distribution partners.

• Strategic priorities for fiscal 2026 include accelerating growth, operational excellence, and U.S. market expansion.

Financial highlights

• Fiscal Q4 2025 revenue reached $843,884, up 16% year-over-year and quarter-over-quarter.

• Full-year revenue for 2025 was $3,052,532, slightly down from $3,111,781 in 2024.

• Gross profit for 2025 was $1,246,859, compared to $1,425,626 in 2024.

• Net loss attributable to the company was $(10,568,733) for 2025, compared to $(10,156,759) in 2024.

• Net loss per share was $(2.00) for 2025, versus $(6.38) in 2024, with higher average shares outstanding.

Outlook and guidance

• Focus remains on achieving FDA clearance for broader U.S. market entry and continued international expansion.

• The company expects the accelerated pace of new account growth to continue into the future.